Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEVANTE: dose-ranging study of inhaled AZD8630 in adults with uncontrolled asthma at risk of exacerbations
CTR20250918Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of azd8630 in asthma, sponsored by AstraZeneca. Started Jun 2025; status: completed.
02
Drugs
azd8630
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20250918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250918.